Can Doximity's New AI Suite Drive the Growth It Needs?
DOCS reports stronger Q1 results and is betting on its new AI suite -- Scribe, GPT, and Pathway -- to drive its next growth phase.
Zacks·23h ago
More News
Certara, Inc. (CERT) Q2 Earnings Miss Estimates
Certara (CERT) delivered earnings and revenue surprises of -30.00% and +0.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Eton Pharmaceuticals (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
Certara, Inc. (CERT) Reports Next Week: Wall Street Expects Earnings Growth
Certara (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of +26.83% and +15.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
Do Options Traders Know Something About Certara Stock We Don't?
Investors need to pay close attention to CERT stock based on the movements in the options market lately.
Zacks·3mo ago
Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?
Certara (CERT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks·3mo ago
VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait?
Veeva Systems gains momentum as strong earnings, Vault CRM growth, and new AI tools reinforce its life sciences edge.
Zacks·3mo ago
Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?